沃华医药董事张戈拟减持股份，最高不超过0.33%公司总股本——投资者需关注的关键信息
【2026年5月7日，山东潍坊报道】山东沃华医药科技股份有限公司（证券代码：002107，简称“沃华医药”）于2026年5月7日发布重要公告，公司董事、董事会秘书张戈先生计划于2026年6月1日至2026年8月31日期间，减持其所持公司股份不超过1,886,016股，占公司总股本的0.33%。本次减持将采用集中竞价交易方式进行。
一、公告核心要点
- 减持主体：董事、董事会秘书张戈先生。
- 持股现状：目前持有公司7,544,065股股份，占总股本1.31%。
- 减持计划：拟自公告披露15个交易日后的三个月内（即2026年6月1日至2026年8月31日），通过集中竞价方式减持不超过1,886,016股（占总股本0.33%）。
- 减持原因：个人资金需求。
- 股份来源：包含公司首次公开发行前持有股份及历年分红送股获得股份。
- 减持价格：将以减持时市场价格为准，若期间公司有派息、送股、转增股本、配股等除权除息事项，减持价格区间及股份数将作相应调整。
二、对股东和投资者的重要影响
- 潜在价格敏感信息：
- 董事和高管减持股份通常被市场视作信心信号，可能会引发投资者对公司治理、未来业绩或股价表现的关注。
- 本次减持规模约占总股本的0.33%，虽然比例不大，但张戈为董事及董事会秘书，其减持行为可能引发市场对公司管理层信心和公司前景的进一步解读。
- 公司控制权和治理结构：公司明确表示，张戈先生并非公司控股股东或实际控制人，本次减持不会导致公司控制权发生变更，亦不会影响公司的治理结构和持续经营能力。
- 合规性：张戈先生严格遵守此前所作限售及减持承诺，并将按照相关法律法规进行信息披露，减持行为不存在违规情形。
- 不确定性提示：张戈先生将视市场情况、股价波动等因素决定是否实施及何时实施本次减持计划，存在减持时间、价格及是否按期完成的不确定性。
三、法律法规及承诺履行情况
张戈先生在公司上市时承诺，上市后12个月内不转让发行前股份，任职期间每年转让不超过所持股份25%，离职半年内不转让股份。截至公告日，所有承诺均已严格履行，无违约情况。本次减持计划亦符合中国证监会及深交所相关规定。
四、投资者应关注的风险提示
- 本次减持计划存在减持时间、减持价格及是否实施完成的不确定性。
- 减持不会影响公司控制权和治理结构。
- 公司将持续督促张戈先生依法合规减持，并及时履行信息披露义务。
五、结语
总结来看，沃华医药董事张戈的减持计划虽然规模不大，但由于其公司高管身份及股份变动行为，仍然具有一定的信息敏感性。投资者应密切关注后续公司公告及市场动态，合理评估减持行为对股价的潜在影响。
免责声明：本文内容仅供投资者参考，不构成任何投资建议。投资者据此操作，风险自担。
English Version: Key Details on Planned Share Reduction by Director of Wohua Pharma
[Weifang, Shandong, May 7, 2026] Shandong Wohua Pharmaceutical Technology Co., Ltd. (Stock Code: 002107, “Wohua Pharma”) announced on May 7, 2026, that its Director and Board Secretary, Mr. Zhang Ge, plans to reduce his shareholding by no more than 1,886,016 shares (0.33% of total shares) via centralized bidding between June 1, 2026, and August 31, 2026.
Key Points from the Announcement
- Subject: Director & Board Secretary Mr. Zhang Ge
- Current Holding: 7,544,065 shares (1.31% of total shares)
- Planned Reduction: Up to 1,886,016 shares (0.33% of total shares) via centralized bidding from June 1, 2026, to August 31, 2026
- Reason: Personal funding needs
- Share Source: Shares held before IPO and bonus shares from previous years
- Reduction Price: Will be determined by market price at the time of reduction, subject to adjustments for ex-dividend or other corporate actions
Important Information for Investors
- Price Sensitive Information:
- Share reduction by directors or senior management can be viewed by the market as a signal regarding management confidence, potentially affecting share price.
- Although the reduction ratio is not large, as Mr. Zhang is a board member and secretary, his action may draw market attention to company management’s confidence and future prospects.
- Control and Governance: The reduction will not affect the company’s control structure or ongoing operations, as Mr. Zhang is not a controlling or actual shareholder.
- Compliance: All prior lock-up and reduction commitments have been strictly followed; the planned reduction complies with regulatory requirements.
- Uncertainties: The plan is subject to market conditions and may not be executed as planned in terms of timing, price, or completion.
Risk Reminders for Investors
- There is uncertainty regarding timing, pricing, and completion of the reduction plan.
- The reduction will not affect company control or governance.
- The company will ensure regulatory compliance and timely disclosures throughout the process.
Conclusion
While the reduction scale is relatively small, its execution by a senior director makes this event noteworthy for investors. Market participants should pay close attention to subsequent announcements and price movements to assess potential impacts on share value.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should make decisions at their own risk.
